Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

Conclusion:
In T2DM patients with the two common vascular risk factors of hypertension and microalbuminuria, linagliptin achieved significant improvements in glycemic control. In this vulnerable patient population at high risk for micro- and macrovascular complications, linagliptin was well tolerated.

Source: Cardiovascular Diabetology - April 9, 2013 Category: Cardiology Authors: Maximilian von EynattenYan GongAngela EmserHans-Juergen Woerle Source Type: research